Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Sapporo, Japan Clinical Trials

A listing of Sapporo, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (8) clinical trials

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.

Phase

0.0 miles

Learn More »

Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer in the expansion part 1 and in participants with adenoid cystic …

Phase

0.02 miles

Learn More »

A Phase 1/2 Study of TAK-788 in Japanese Patients

The drug being tested in this study is called TAK-788. TAK-788 is being tested to treat Japanese participants with NSCLC. This study has two parts (Phase 1 part and Phase 2 part), Phase 1 part of this study will look at the safety, efficacy, tolerability and PK of TAK-788 orally …

Phase

0.02 miles

Learn More »

A Study of MORAb-202 in Participants With Solid Tumors

The primary objective of this study is to evaluate the tolerability and safety profile of MORAb-202 in participants with solid tumors.

Phase

0.02 miles

Learn More »

A Phase 1 Study Of Talazoparib PARP Inhibitor In Japanese Patients With Advanced Solid Tumors

This is a Phase 1 study which consists of 2 parts; Dose Escalation part and Expansion part. The dose escalation part is openlabel, and evaluates safety, preliminary efficacy and PK of singleagent talazoparib in sequential cohorts of adult patients with advanced solid tumors who are resistant to standard therapy or …

Phase

1.08 miles

Learn More »

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

The purpose of this study is to determine the recommended Phase 2 dose and evaluate safety profile of cusatuzumab in combination with azacitidine in Japanese participants with treatment nave acute myeloid leukemia (AML) who are not candidates for intensive treatment.

Phase

1.16 miles

Learn More »

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

This is a multicenter, open-label Phase 1 study of acalabrutinib, a selective and irreversible Bruton's tyrosine kinase inhibitor, in Japanese adult patients with advanced B-cell malignancies. This study is divided into 3 parts: Part 1 (dose-confirmation phase), Part 2 (dose-expansion phase) and Part 3 (dose-confirmation phase for combination therapy).

Phase

1.23 miles

Learn More »

A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after a single intravenous dose of E3112 in Japanese healthy adult male participants.

Phase

4.56 miles

Learn More »